| structure-activity relationship | The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Other factors contributing to structure-activity relationship include chemical reactivity, electronic effects, resonance, and inductive effects. (12 Dec 1998) |
|---|---|
| nonsuppressible insulin-like activity | A blood protein (nsila) which mimics the biological activity of insulin in serum, but is not suppressed by insulin antibodies. During acid-ethanol extraction of cohn fraction III, 10% of the activity is found in the supernatant (nsila-s) and the remaining activity in the precipitate (nsila-p). The latter is a large molecular compound, much less stable than the soluble fraction. Nsila-s is a more potent growth factor than insulin and exhibits sulfation activity. (12 Dec 1998) |
| drug activity | A measure of the physiological response a drug produces. A less active drug produces less response (and visa versa). (12 Dec 1998) |
| insulin-like activity | A measure of substances, usually in plasma, that exert biologic effects similar to those of insulin in various bioassays; sometimes used as a measure of plasma insulin concentrations; always gives higher values than immunochemical techniques for the measurement of insulin. (05 Mar 2000) |
| intrinsic sympathomimetic activity | The property of a drug that causes activation of adrenergic receptors so as to produce effects similar to stimulation of the sympathetic nervous system. (05 Mar 2000) |
| optical activity | The ability of a material to rotate the plane of polarized light. (09 Oct 1997) |
| triggered activity | One or a series of spontaneously generated heart beats originating from an action potential that produces an after-depolarisation which reaches activation threshold. (05 Mar 2000) |
| unit of thyrotrophic activity | The activity of an amount of an extract of the anterior lobe of the hypophysis which, given daily for 5 days, will cause the thyroid of a guinea pig (weighing 200 g) to reach a weight of 600 mg. (05 Mar 2000) |
| zone of polarizing activity | <cell biology> The small group of mesenchyme cells in avian limb buds that is located at the posterior margin of the developing bud and that produces a substance, possibly retinoic acid, that provides positional information to the developing limb bud. (18 Nov 1997) |
| radical mastectomy, total | Breast cancer treatment involving removal of the breast, the pectoral (chest) muscles, lymph nodes (the glands ) in the armpit and associated skin and subcutaneous tissue. (12 Dec 1998) |
| male chromosome complement | The large majority of males have a 46, xy chromosome complement (46 chromosomes including an x and a y chromosome). A minority of males have other chromosome constitutions such as 47,xxy (47 chromosomes including two x chromosomes and a y chromosome) and 47,xyy (47 chromosomes including an x and two y chromosomes). (12 Dec 1998) |
| genetic complement | <biology, genetics> The set of chromosomes contained within any one particular cell. (07 May 1998) |
| receptors, complement | Molecules on the surface of some B-lymphocytes and macrophages, that recognise and combine with the c3b, c3d, c1q, and c4b components of complement. (12 Dec 1998) |
| receptors, complement 3b | Molecular sites on or in some B-lymphocytes and macrophages that recognise and combine with complement 3b. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids. (12 Dec 1998) |
| receptors, complement 3d | Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognise and combine with complement 3d. Human cr2 serves as a receptor for both c3dg and the gp350/220 glycoprotein of herpes virus 4, human, and binds the monoclonal antibody okb7, which blocks binding of both ligands to the receptor. (12 Dec 1998) |